Solid biosciences received fda clinical hold letter for sgt-001 program

Solid biosciences provides data update from sgt-001 development program.solid biosciences inc - received fda clinical hold letter.solid biosciences inc - received fda clinical hold letter and is working to respond and determine a path to resume dosing.solid biosciences- sgt-001 has potential to provide therapeutic benefit for patients with duchenne.
SLDB Ratings Summary
SLDB Quant Ranking